Worth reading
40Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
3718
¥ millionWording
Conditional
How definitive the wording is.Items stated in the management plan
FormulatedKey initiatives
01Promoting business growth
02Expanding the member base for part-time physician placement
03Expanding full-time physician placement based on the member base
04Effective use of the member base across the Group
05Selection and Concentration in Our Businesses
06Enhancing disclosure on medium- to long-term policies and growth strategies aimed at increasing corporate value
07Clarification of medium-term targets and milestones
08Expanding disclosure materials
09More comprehensive explanations regarding market capitalization and PBR
10Enhancement of IR activities (more continuous and constructive dialogue with investors)
11Expanding investor meetings
12Holding briefings regularly
13Expanding disclosure in English
Risks identified by the company
If the Company fails to meet the market capitalization criterion during the improvement period ending 31 December 2026, the Tokyo Stock Exchange will designate it as a security under supervision.
If, following the subsequent review, the Company is not confirmed to be in compliance with the market capitalization criterion, it will be designated as a delisting issue and delisted on 1 July 2027.
| Item | Details |
|---|---|
| Plan name | Plan for Compliance with the Listing Maintenance Criteria (Including the Improvement Period) |
| Plan period | Through 31 December 2026 |
| Progress against the plan | Formulated |
| Key initiatives | Promoting business growth, Expanding the member base for part-time physician placement, Expanding full-time physician placement based on the member base, Effective use of the member base across the Group, Selection and Concentration in Our Businesses, Enhancing disclosure on medium- to long-term policies and growth strategies aimed at increasing corporate value, Clarification of medium-term targets and milestones, Expanding disclosure materials, More comprehensive explanations regarding market capitalization and PBR, Enhancement of IR activities (more continuous and constructive dialogue with investors), Expanding investor meetings, Holding briefings regularly, Expanding disclosure in English |
| Risks identified | If the Company fails to meet the market capitalization criterion during the improvement period ending 31 December 2026, the Tokyo Stock Exchange will designate it as a security under supervision., If, following the subsequent review, the Company is not confirmed to be in compliance with the market capitalization criterion, it will be designated as a delisting issue and delisted on 1 July 2027. |
| Publication date | 31 March 2026 |
Items this document does not state (19)
Sales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsPlan assumptionsResults under the previous planReason for revision or withdrawalSize of the Target MarketDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company recognizes that a gap has emerged between its market valuation and its underlying value because the progress of its initiatives relating to earnings capacity and growth, as well as the visualization of that progress, has not been sufficiently communicated to the capital markets, among other factors.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.